Diphencyprone as a therapeutic option in cutaneous metastasis of melanoma. A single-institution experience

• Published in: Anais brasileiros de dermatología Vol. 93; no. 2; pp. 299 - 301
• Main Authors: Gibbons, Ivana Lameiras, Sonagli, Marina, Bertolli, Eduardo, Macedo, Mariana Petaccia de, Pinto, Clovis Antonio Lopes, Duprat Neto, João Pedreira
• Format: Journal Article
• Language: English; Portuguese
• Published: Spain Sociedade Brasileira de Dermatologia 01.03.2018
• Subjects: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Biopsy; Brazil; Communication; Cyclopropanes - therapeutic use; DERMATOLOGY; Female; Humans; Male; Melanoma; Melanoma - drug therapy; Melanoma - pathology; Melanoma - secondary; Middle Aged; Neoplasm metastasis; Skin Neoplasms - drug therapy; Skin Neoplasms - pathology; Skin Neoplasms - secondary; Therapeutics; Treatment Outcome; Young Adult; Neoplasm metastasis; Melanoma; Therapeutics
• ISSN: 0365-0596; 1806-4841; 1806-4841
• DOI: 10.1590/abd1806-4841.20187162

Diphencyprone has been reported as a local immunotherapy for cutaneous melanoma metastases. We aim to report cases of melanoma patients treated with diphencyprone in a single Brazilian institution and highlight their outcomes. Since 2012, we have treated 16 melanoma patients with cutaneous metastases with topical diphencyprone. To date, we have had 37.5% of complete response, 25% of partial responses, and 31.25% patients without any response. Treatment was well tolerated and local toxicity was easily controlled. We believe topical diphencyprone is a feasible treatment that can be another option for treating melanoma patients, especially in cases of in-transit or extensive disease.